Antibody Improves Survival in Gastric Cancer.
Results from a randomized phase II study indicate that adding the experimental antibody IMAB362, which targets the tight junction protein claudin18.2, to standard chemotherapy is more effective than chemotherapy alone in previously untreated patients with advanced gastric cancer. IMAB362 extended progression-free and overall survival by 3.1 months and 4.8 months, respectively.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D018572:Disease-Free Survival; D015251:Epirubicin / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D013274:Stomach Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D015251:Epirubicin; D000069287:Capecitabine; C585662:zolbetuximab